Carna Biosciences, Inc.
TTSE:4572355.00
JPY
-12.00
(-3.27%)
ISIN
JP3220550002
Return %
Stock
S&P 500
1Y
67.45
14.20
3Y
-50.69
81.12
5Y
-64.50
68.34
Capital Structure
JPY
•
in mil. unless spec.Working Capital
JPY
•
in mil. unless spec.Growth Rates
JPY
•
in mil. unless spec.Quarterly Revenue
JPY
•
in mil. unless spec.Quarterly Earnings Per Share
JPY
•
in mil. unless spec.Quarterly Dividends Per Share
JPY
•
in mil. unless spec.Company Description
- CEO
- Kohichiro Yoshino
- Full Time Employees
- 61
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- BMA, 1-5-5 Minatojima-Minamimachi Kobe HY Japan 650-0047
- IPO Date
- Mar 25, 2008
- Website
- carnabio.com
- Similar Companies
- Business
- Carna Biosciences, Inc. specializes in drug discovery research support, with a core focus on kinase proteins and kinase inhibitor development. The company manufactures and sells kinase proteins, biotinylated kinases, and assay kits for kinase inhibitor drug discovery. It offers profiling and screening services, assay development, and kinase protein profiling for pharmaceutical companies and research institutions. Carna also provides outsourced drug discovery services using various biochemical assay technologies such as fluorescence polarization, TR-FRET, ELISA, and ADP detection technologies. The company supports research programs targeting protein kinases, critical in oncology and neurological diseases. Carna Biosciences operates primarily in Japan but extends its services globally through partnerships and distribution agreements. Founded in 2000 and headquartered in Kyoto, Japan, Carna has strategically collaborated with entities like Evotec AG to accelerate the development of its kinase inhibitor programs, including the CB-1763 program for blood cancers. The company recently announced research collaborations with Sumitomo Pharma aimed at discovering novel kinase inhibitors for psychiatric and neurological disorders. It also maintains licensing agreements with Janssen Biotech to develop kinase inhibitors and has secured funding rounds to support ongoing research and expansion efforts. Recent operational developments include the release of several new biotinylated kinase protein products and the continued advancement of its leading drug candidate, Docirbrutinib, a non-covalent pan-mutant BTK inhibitor currently in Phase 1b clinical studies. Carna has expanded its global reach by signing distribution agreements with European partners such as Bio-Connect BV and KinaseDetect ApS. It also engages in active research partnerships for next-generation therapies, exemplified by the licensing of STING inhibitors for immuno-oncology applications to other biotech firms. These strategic alliances and new product launches reflect Carna’s commitment to innovation and growth in the kinase inhibitor and drug discovery market segments. Carna Biosciences serves pharmaceutical and biotechnology companies focused on oncology, immunology, and neurological disorders. Its comprehensive offerings facilitate drug discovery timelines through proprietary proteins, assays, and collaborative developments. The company’s integrated platform accelerates kinase inhibitor research from early discovery through to clinical trial readiness. Overall, Carna Biosciences, Inc. presents as a specialized biotechnology firm providing essential products and research services in kinase biology, backed by recent expansions in product offerings, strategic partnerships, and advanced clinical development programs since its founding and establishment in Kyoto, Japan.